{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:30:36Z","timestamp":1760956236887,"version":"3.32.0"},"reference-count":69,"publisher":"Southern Medical Association","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.14423\/smj.0000000000000552","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T16:19:48Z","timestamp":1735921188000},"page":"721-729","source":"Crossref","is-referenced-by-count":3,"title":["Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation"],"prefix":"10.14423","volume":"109","author":[{"given":"Rahul H.","family":"Damani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose I.","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5542","reference":[{"key":"key2025010301119380500_bib1","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","journal-title":"Stroke"},{"key":"key2025010301119380500_bib2","first-page":"727","article-title":"The second report of the Cerebral Embolism Task Force","volume":"46","author":"Cardiogenic brain embolism","journal-title":"Arch Neurol"},{"key":"key2025010301119380500_bib3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1161\/01.CIR.31.6.888","article-title":"Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan","volume":"31","journal-title":"Circulation"},{"key":"key2025010301119380500_bib4","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","article-title":"Lifetime risk for development of atrial fibrillation: the Framingham Heart Study","volume":"110","journal-title":"Circulation"},{"key":"key2025010301119380500_bib5","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1161\/01.CIR.96.7.2455","article-title":"Incidence of and risk factors for atrial fibrillation in older adults","volume":"96","journal-title":"Circulation"},{"key":"key2025010301119380500_bib6","first-page":"1561","article-title":"Atrial fibrillation: a major contributor to stroke in the elderly","volume":"147","journal-title":"The Framingham Study Arch Intern Med"},{"key":"key2025010301119380500_bib7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9343(99)80348-9","article-title":"The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study","volume":"98","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"key2025010301119380500_bib8","first-page":"21","article-title":"Can we predict stroke in atrial fibrillation?","volume":"35","journal-title":"Clin Cardiol"},{"key":"key2025010301119380500_bib9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","article-title":"Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited","volume":"373","journal-title":"Lancet"},{"key":"key2025010301119380500_bib10","first-page":"1449","article-title":"Analysis of pooled data from five randomized controlled trials","volume":"154","author":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation","journal-title":"Arch Intern Med"},{"key":"key2025010301119380500_bib11","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","article-title":"Independent predictors of stroke in patients with atrial fibrillation: a systematic review","volume":"69","author":"Stroke Risk in Atrial Fibrillation Working Group","journal-title":"Neurology"},{"key":"key2025010301119380500_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1378\/chest.11-0862","article-title":"Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project","volume":"141","journal-title":"Chest"},{"key":"key2025010301119380500_bib13","first-page":"826.e13","article-title":"Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study","volume":"125","journal-title":"Am J Med"},{"key":"key2025010301119380500_bib14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.amjcard.2008.06.018","article-title":"Relation of atrial fibrillation to glomerular filtration rate","volume":"102","journal-title":"Am J Cardiol"},{"key":"key2025010301119380500_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","journal-title":"N Engl J Med"},{"key":"key2025010301119380500_bib16","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1161\/STR.0b013e318266722a","article-title":"Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"43","journal-title":"Stroke"},{"key":"key2025010301119380500_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cjca.2010.11.007","article-title":"Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter","volume":"27","journal-title":"Can J Cardiol"},{"key":"key2025010301119380500_bib18","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","journal-title":"JAMA"},{"key":"key2025010301119380500_bib19","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1161\/01.CIR.0000145172.55640.93","article-title":"Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin","volume":"110","journal-title":"Circulation"},{"key":"key2025010301119380500_bib20","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.290.20.2685","article-title":"Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?","volume":"290","journal-title":"JAMA"},{"key":"key2025010301119380500_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1160\/TH09-11-0757","article-title":"The CHADS2 score for stroke risk stratification in atrial fibrillation\u2014friend or foe?","volume":"104","journal-title":"Thromb Haemost"},{"key":"key2025010301119380500_bib22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1160\/TH11-02-0061","article-title":"Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis","volume":"106","journal-title":"Thromb Haemost"},{"key":"key2025010301119380500_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation","volume":"137","journal-title":"Chest"},{"key":"key2025010301119380500_bib24","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","journal-title":"BMJ"},{"key":"key2025010301119380500_bib25","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/STROKEAHA.110.609297","article-title":"Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring","volume":"42","journal-title":"Stroke"},{"key":"key2025010301119380500_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1538-7836.2010.04085.x","article-title":"A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice","volume":"9","journal-title":"J Thromb Haemost"},{"key":"key2025010301119380500_bib27","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/STROKEAHA.110.590257","article-title":"Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort","volume":"41","journal-title":"Stroke"},{"key":"key2025010301119380500_bib28","first-page":"e1","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","journal-title":"J Am Coll Cardiol"},{"key":"key2025010301119380500_bib29","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","journal-title":"Eur Heart J"},{"key":"key2025010301119380500_bib30","first-page":"2369","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery","journal-title":"Eur Heart J"},{"key":"key2025010301119380500_bib31","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","journal-title":"Chest"},{"key":"key2025010301119380500_bib32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","article-title":"Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) score","volume":"57","journal-title":"J Am Coll Cardiol"},{"key":"key2025010301119380500_bib33","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1538-7836.2011.04378.x","article-title":"Bleeding risk in \"real world\" patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort","volume":"9","journal-title":"J Thromb Haemost"},{"key":"key2025010301119380500_bib34","first-page":"e257","article-title":"ACC\/AHA\/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society","volume":"114","journal-title":"Circulation"},{"key":"key2025010301119380500_bib35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijcard.2005.07.031","article-title":"Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project","volume":"110","journal-title":"Int J Cardiol"},{"key":"key2025010301119380500_bib36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/hs0102.101817","article-title":"Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project","volume":"33","journal-title":"Stroke"},{"key":"key2025010301119380500_bib37","first-page":"175","article-title":"Patients' understanding of anticoagulant therapy in a multiethnic population","volume":"96","journal-title":"J R Soc Med"},{"key":"key2025010301119380500_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1345\/aph.1A198","article-title":"Relationship between patients' warfarin knowledge and anticoagulation control","volume":"37","journal-title":"Ann Pharmacother"},{"key":"key2025010301119380500_bib39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2261-10-21","article-title":"TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT)","volume":"10","journal-title":"BMC Cardiovasc Disord"},{"key":"key2025010301119380500_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2296-12-17","article-title":"Practice nursed-based, individual and video-assisted patient education in oral anticoagulation\u2014protocol of a cluster-randomized controlled trial","volume":"12","journal-title":"BMC Fam Pract"},{"key":"key2025010301119380500_bib41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1472-6963-11-16","article-title":"A role for pharmacists in community-based post-discharge warfarin management: protocol for the \"the role of community pharmacy in post hospital management of patients initiated on warfarin\" study","volume":"11","journal-title":"BMC Health Serv Res"},{"key":"key2025010301119380500_bib42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev.med.070808.170037","article-title":"Pharmacogenetics of warfarin","volume":"61","journal-title":"Annu Rev Med"},{"key":"key2025010301119380500_bib43","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","journal-title":"Ann Intern Med"},{"key":"key2025010301119380500_bib44","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke","volume":"342","author":"European Atrial Fibrillation Trial Study Group","journal-title":"Lancet"},{"key":"key2025010301119380500_bib45","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","article-title":"Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial","volume":"348","journal-title":"Lancet"},{"key":"key2025010301119380500_bib46","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.STR.0000258004.64840.0b","article-title":"Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials","volume":"38","journal-title":"Stroke"},{"key":"key2025010301119380500_bib47","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","journal-title":"Circulation"},{"key":"key2025010301119380500_bib48","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1503\/cmaj.061523","article-title":"Frequency of adverse events in patients with poor anticoagulation: a meta-analysis","volume":"176","journal-title":"CMAJ"},{"key":"key2025010301119380500_bib49","first-page":"1903","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"ACTIVE Writing Group of the ACTIVE Investigators","journal-title":"Lancet"},{"key":"key2025010301119380500_bib50","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"ACTIVE Investigators","journal-title":"N Engl J Med"},{"key":"key2025010301119380500_bib51","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","journal-title":"N Engl J Med"},{"key":"key2025010301119380500_bib52","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","journal-title":"Lancet Neurol"},{"key":"key2025010301119380500_bib53","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","journal-title":"N Engl J Med"},{"key":"key2025010301119380500_bib54","unstructured":"Australian Government Department of Health, Therapeutic Goods Administration. Dabigatran (Pradaxa) (all alerts). \nhttps:\/\/www.tga.gov.au\/node\/369. Accessed August 29, 2016."},{"key":"key2025010301119380500_bib55","unstructured":"European Medicines Agency. European Medicines Agency updates on safety of Pradaxa. November 18, 2011. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2011\/11\/WC500117818.pdf. Accessed July 31, 2016."},{"key":"key2025010301119380500_bib56","unstructured":"Food and Drug Administration. FDA approves anti-clotting drug Savaysa. \nhttp:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm429523.htm. Published January 8, 2015. Accessed July 31, 2016."},{"key":"key2025010301119380500_bib57","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","journal-title":"N Engl J Med"},{"key":"key2025010301119380500_bib58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","journal-title":"Lancet Neurol"},{"key":"key2025010301119380500_bib59","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","journal-title":"Circulation"},{"key":"key2025010301119380500_bib60","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/clc.22373","article-title":"Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban","volume":"38","journal-title":"Clin Cardiol"},{"key":"key2025010301119380500_bib61","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","journal-title":"N Engl J Med"},{"key":"key2025010301119380500_bib62","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","journal-title":"N Engl J Med"},{"key":"key2025010301119380500_bib63","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1161\/STROKEAHA.112.673558","article-title":"Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials","volume":"43","journal-title":"Stroke"},{"key":"key2025010301119380500_bib64","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","journal-title":"N Engl J Med"},{"key":"key2025010301119380500_bib65","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/CIRCULATIONAHA.110.985655","article-title":"Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation","volume":"123","journal-title":"Circulation"},{"key":"key2025010301119380500_bib66","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/STROKEAHA.111.000402","article-title":"Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation","volume":"44","journal-title":"Stroke"},{"key":"key2025010301119380500_bib67","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/jama.2014.339","article-title":"Rethinking warfarin for atrial fibrillation","volume":"311","journal-title":"JAMA"},{"key":"key2025010301119380500_bib68","first-page":"1483","article-title":"Direct-acting oral anticoagulants: the brain gets a break","volume":"70","journal-title":"JAMA Neurol"},{"key":"key2025010301119380500_bib69","first-page":"CD008980","article-title":"Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation","volume":"8","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Southern Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/sma.org\/southern-medical-journal\/article\/secondary-stroke-prevention-in-nonvalvular-atrial-fibrillation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T16:20:02Z","timestamp":1735921202000},"score":1,"resource":{"primary":{"URL":"https:\/\/sma.org\/southern-medical-journal\/article\/secondary-stroke-prevention-in-nonvalvular-atrial-fibrillation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":69,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.14423\/SMJ.0000000000000552"],"URL":"https:\/\/doi.org\/10.14423\/smj.0000000000000552","relation":{},"ISSN":["1541-8243","0038-4348"],"issn-type":[{"value":"1541-8243","type":"electronic"},{"value":"0038-4348","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}